All deals
You are viewing a shared deal. With a free account you access the full showcase and talk directly with whoever manages the deal.
Biotech in gene therapies for neurodegenerative disease
Capital Raising Live

Biotech in gene therapies for neurodegenerative disease

Seed
Round stage
Italy
Italy
Startup
SeedRound stage
AnyMinimum ticket
LiveStatus

Who they are & what they do

SectorHealthcare
Industries
BiotechnologyGene Therapy
Company overview

Developing a novel gene therapy for Huntington's disease, one of the largest unmet needs among rare neurodegenerative disorders. Its core technology is a "molecular switch" based on the MTF1 gene, designed to reduce the toxicity of the mutant huntingtin protein that drives disease progression, delivered via AAV or mRNA vectors.

The company was founded in April 2024 by a team of University of Padua scientists, with support from the Golinelli Foundation and Italy's PNRR biotech funding stream, and is completing its formal recognition as a University of Padua academic spin-off — a step needed to access private and venture capital to scale its R&D program.

Key clients & traction

Huntington's patientsPharma licensing partnersRare-disease research institutes
Company type Startup
Founded / established 2024
Country Italy

Website: Confidential

Why look at this deal

Highlights

  1. 01Targets Huntington's disease
  2. 02Proprietary MTF1 switch
  3. 03University of Padua
  4. 04Golinelli Foundation backing
  5. 05PNRR-funded research

Deal snapshot

Round stageSeed
InstrumentEquity
Minimum ticketAny
Pre-money valuation Confidential
Equity offeringConfidential
Revenue LTM50k
Patents1 underlying patent (Therapeutic factors for the treatment of PolyQ diseases)

Locked fields are disclosed after expressing interest.

Data room

Public files are open to everyone. The rest unlock once you qualify.

For companies and advisors

Have a deal to bring to market?

Publish your deal on UCapital Dealflow and reach qualified buyers and investors. Data room, NDA and lead management included.

Disclaimer

UCapital Asset Management LLP is authorised and regulated by the Financial Conduct Authority (FCA) in the United Kingdom and by CONSOB in Italy, and operates in the United States through FINRA-licensed US partners and affiliates.

This platform serves informational and technological purposes only: it executes no market transactions, does not constitute a solicitation to invest and provides no financial advice of any kind. The platform lets users manage a deal through the technological tools made available to them, such as the CRM for lead tracking and analytics. No capital raising and no sale is executed on or through the platform: each individual deal is executed offline by the designated regulated entities, in accordance with the regulations in force in each country, their compliance frameworks and under their full responsibility.

The content is intended exclusively for eligible counterparties, professional investors and professional clients as defined by applicable regulations, and does not constitute a public offer. The information is not directed at persons in jurisdictions where its distribution or use would be contrary to local laws or regulations.

The data shown on these pages is public data or data collected and processed by UCapital. For user-created deals, the data is entered by the users themselves, who take full responsibility for what is published: the publication of a deal on the platform does not constitute a recommendation, endorsement or verification by UCapital.

The data shown may not always be real-time and may differ from what is verified in due diligence when contacting the regulated entities responsible for managing the deal. Any prices, valuations and projections are purely indicative.

Every investment carries risks, including the total loss of the capital invested. Past performance is not indicative of future results. Before any decision, investors must carry out their own assessments and consult the regulated entities managing the deal and, where appropriate, their own legal, tax and financial advisers.